

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10758488
Filing Date		2004-01-15
First Named Inventor	Gorenstein	
Art Unit	1635	
Examiner Name	Vivlenmore, Tracy Ann	
Attorney Docket Number	UTMB:1019RCE	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.V./

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5270163		1993-12-14	GOLD, et al.	
	2	5475096		1995-12-12	GOLD, et al.	
	3	5582981		1996-12-10	TOOLE, et al.	
	4	5639603		1997-06-17	DOWER, et al.	
	5	5663153		1997-09-02	HUTCHERSON, et al.	
	6	5668265		1997-09-16	NADEAU, et al.	
	7	5670637		1997-09-23	GOLD, et al.	
	8	5696249		1997-12-09	GOLD, et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10758488
Filing Date		2004-01-15
First Named Inventor	Gorenstein	
Art Unit	1635	
Examiner Name	Vivlemore, Tracy Ann	
Attorney Docket Number	UTMB:1019RCE	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.V./

	9	5756291		1998-05-26	GRIFFIN, et al.	
	10	5844106		1998-12-01	SEELA, et al.	
	11	6171792	B2	2001-01-09	BRENT, et al.	
	12	6180348	B1	2001-01-30	LI	
	13	6346611	B1	2002-02-12	PAGRATIS, et al.	
	14	6369208	B1	2002-04-09	COLE, et al.	
	15	6514948	B1	2003-02-04	RAZ, et al.	
	16	6551795	B1	2003-04-22	RUBENFIELD, et al.	
	17	6610504	B1	2003-08-26	YUAN	
	18	6713616	B2	2004-03-30	PAGRATIS, et al.	
	19	6716629	B1	2004-04-06	HESS, et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10758488
Filing Date	2004-01-15
First Named Inventor	Gorenstein
Art Unit	1635
Examiner Name	Vivlemore, Tracy Ann
Attorney Docket Number	UTMB:1019RCE

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.V./

	20	6867289	B1	2005-03-15	GORENSTEIN, et al.	
--	----	---------	----	------------	--------------------	--

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20010014461	A1	2001-08-16	HUTCHENS, et al.	
	2	20010014479	A1	2001-08-16	HUTCHENS, et al.	
	3	20010034330	A1	2001-10-25	KENSIL	
	4	20030133229	A1	2003-07-31	KLINMAN, et al.	
	5	20030162190	A1	2003-08-28	GORENSTEIN, et al.	
	6	20030162216	A1	2003-08-28	GOLD, et al.	
	7	20030186906	A1	2003-10-02	SCHLINGENSIEPEN, et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS

Remove

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10758488
Filing Date	2004-01-15
First Named Inventor	Gorenstein
Art Unit	1635
Examiner Name	Vivemore, Tracy Ann
Attorney Docket Number	UTMB:1019RCE

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.V./

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0 855 184	EP	A1	1998-07-29	LIPFORD, et al.		<input type="checkbox"/>
	2	99/54506	WO	A1	1999-10-28	LI		<input type="checkbox"/>
	3	00/24404	WO	A1	2000-05-04	GORENSTEIN, et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	AMARZGUIQUI, M., et al., Nuc Acids Res, 31, 589-595, (2003) – Tolerance for mutations and chemical modifications in a siRNA	<input type="checkbox"/>
	2	ANDREOLA, M., et al., "Towards the Selection of Phosphorothioate Aptamers: Optimizing In Vitro Selection Steps with Phosphorothioate Nucleotides," European Journal of Biochemistry 267:5032-5040	<input type="checkbox"/>
	3	BRAASCH, D.A., et al., Nucleic Acids Res, 30(23), 5160-7 (2002) -Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design	<input type="checkbox"/>
	4	BRAASCH, D.A. AND D.R. COREY, Biochemistry, 41, 4503-4510 (2002) - Novel antisense and peptide nucleic acid strategies for controlling gene expression	<input type="checkbox"/>
	5	CAPLEN, N.J., et al., PNAS, 98, 9742-9747 (2001) – Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10758488
Filing Date	2004-01-15
First Named Inventor	Gorenstein
Art Unit	1635
Examiner Name	Vivemore, Tracy Ann
Attorney Docket Number	UTMB:1019RCE

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.V./

6	CASSIDAY, L., et al., "In Vivo Recognition of an RNA Aptamer by its Transcription Factor Target," Biochemistry (2001), 40:2433-3438	<input type="checkbox"/>
7	CHI, J.T., PNAS, 100(11), 6343-6 (2003) - Genomewide view of gene silencing by small interfering RNAs.	<input type="checkbox"/>
8	ELBASHIR, et al., "RNA Interference is Mediated by 21- and 22- nucleotide RNAs," Genes and Development (2001), 15:188-200	<input type="checkbox"/>
9	ELGEMEIE, "Thioguanine, Mercaptoputine: Their Analogs and Nucleosides as antimetabolites," Current Pharmaceutical Design (2003), 9:2627-2642	<input type="checkbox"/>
10	FIRE, et al., Nature, 391, 806 (1998) – Potent and specific genetic interference by dsRNA in C.elegans	<input type="checkbox"/>
11	GITLIN, L., et al., Nature, 418, 430-434 (2002) – Short interfering RNA confers intracellular antiviral immunity in human cells.	<input type="checkbox"/>
12	HU, W., et al., Curr Biol, 12, 1301-1311 (2002) – Inhibition of retroviral pathogenesis by RNA interference.	<input type="checkbox"/>
13	JACKSON, A.L., et al., Nat Biotech, 21(6), 635-637 (2003) – Expression profiling reveals off-target gene regulation by RNAi.	<input type="checkbox"/>
14	JACQUE, J.M., et al., Nature, 418, 435-438 (2002) – Modulation of HIV-1 replication by RNA interference.	<input type="checkbox"/>
15	JANSEN, B. AND U. ZANGEMEISTER-WITTE, Lancet Oncol, 3, 672-683 (2002) – Antisense therapy for cancer--the time of truth.	<input type="checkbox"/>
16	KANAORI, et al., "Effect of Phosphorothioate Chirality on i-Motif Structure and Stability," Biochemistry (2004), 43:5672-5679	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10758488
Filing Date	2004-01-15
First Named Inventor	Gorenstein
Art Unit	1635
Examiner Name	Vivemore, Tracy Ann
Attorney Docket Number	UTMB:1019RCE

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.V./

17	KAWASAKI, H., et al (Taira), Nuc Acids Res, 31(3), 981-987 (2003) – siRNAs generated by recombinant human Dicer include specific and significant but target site-independent gene silencing in human cells.	<input type="checkbox"/>
18	KING, D. et al., "Combinatorial Selection and Binding of Phosphorothioate Aptamers Targeting Human NF-kappa B RelA (p65) and p50," Biochemistry (2002), 41:9696-9706	<input type="checkbox"/>
19	KING, D.J., "Selection, Binding and Design of Phosphorothioate Duplex Aptamers for the Transcription Factors NF-IL6 and NP-KB," dissertation August 2001	<input type="checkbox"/>
20	KOLLER, E., et al., Trends Pharm Sci, 21, 142-148 – Elucidating cell signaling mechanisms using antisense technology.	<input type="checkbox"/>
21	LESCAR, J., et al., Cell 105(1), 137-48. (2001) - The fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH.	<input type="checkbox"/>
22	MCCAFFREY, A.P., et al., Nat Biotechnol, 21(6), 639-44 (2003) - Inhibition of hepatitis B virus in mice by RNA interference	<input type="checkbox"/>
23	MILLER, V.M., et al., PNAS, 100(12), 7195-200 - Allele-specific silencing of dominant disease genes	<input type="checkbox"/>
24	NOVINA, C.D., et al., Nat Med, 8, 681-686 (2002) – siRNA-directed inhibition of HIV-1 infection	<input type="checkbox"/>
25	PLETNEV, S.V., et al., Cell 105(1), 127-36 (2001) - Locations of carbohydrate sites on alphavirus glycoproteins show that E1 forms an icosahedral scaffold.	<input type="checkbox"/>
26	RAVEH, S., "Peptidic Determinants and Structural Model of Human NDP kinase B Bound in Single-Stranded DNA," Biochemistry (2001), 40:5882-5893	<input type="checkbox"/>
27	SAZANI, et al., "Nuclear Antisense Effects of Neutral Anionic and Cationic Oligonucleotide Analogs," Nucleic Acids Research (2001), 29:3965-3974	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10758488
Filing Date	2004-01-15
First Named Inventor	Gorenstein
Art Unit	1635
Examiner Name	Vivemore, Tracy Ann
Attorney Docket Number	UTMB:1019RCE

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.V./

28	SEMIZAROV, D., et al., PNAS, 100(11), 6347-52 (2003) - Specificity of short interfering RNA determined through gene expression signatures.	<input type="checkbox"/>
29	SONG, E., et al., Nat Med, 9, 347-351 (2003) – RNA interference targeting Fas protects mice from fulminant hepatitis.	<input type="checkbox"/>
30	SONG, E., et al., J Virol. 2003 Jul;77(13):7174-81 (2003) - Sustained small interfering RNA-mediated Human Immunodeficiency Virus Type 1 inhibition in primary macrophages.	<input type="checkbox"/>
31	UEDA, TAKUYA, et al. (1991) Phosphorothioate-containing RNAs show mRNA activity in the prokaryotic translation systems in vitro. Nucleic Acids Research, Vol. 19, No. 3, pp. 547-552.	<input type="checkbox"/>
32	XIA, H.B. et al. Nat Biotech, 20, 1006-1010 (2002) – siRNA-mediated gene silencing in vitro and in vivo.	<input type="checkbox"/>
33	YANG, X., et al., "Construction and Selection of Bead-Bound Combinatorial Oligonucleoside Phosphorothioate and Phosphorodithioate Aptamer Libraries Designed for Rapid PCR-Based Sequencing," Nucleic Acid Research (2002), 30:132-140	<input type="checkbox"/>
34	YOKOTA, T., et al. (Taira), EMBO Rep., 4(6), 602-608 (2003) – Inhibition of intracellular hepatitis C virus by synthetic and vector-derived small interfering RNAs.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button **Add**

EXAMINER SIGNATURE

Examiner Signature	/Tracy Vivemore/	Date Considered	03/16/2008
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.